Table 1.
Demographics and baseline clinical characteristics (n = 19).
| Age (years), mean (SD) | 42.79 (13.8) |
| Age range (years) | 20–61 |
| Gender, n (%) | |
| Female | 13 (68.4) |
| Male | 6 (31.5) |
| Education level, n (%) | |
| High School | 2 (10.5) |
| Some college | 1 (5.2) |
| College | 11 (57.8) |
| Masters | 5 (26.3) |
| Marital/Relationship status, n (%) | |
| Married | 7 (36.8) |
| Domestic partnership | 2 (10.5) |
| Single | 10 (52.6) |
| Employment Status, n (%) | |
| Unemployed | 3 (15.7) |
| Full-time employed | 7 (36.8) |
| Part-time employed | 9 (47.3) |
| Race, n (%) | |
| White | 16 (84.2) |
| Black | 2 (10.5) |
| Two or more race | 1 (5.2) |
| Ethnic origin, n (%) | |
| Hispanic | 2 (10.5) |
| Non-Hispanic | 17 (89.4) |
| Time since MDD diagnosis (years)/Estimated illness duration (years), mean (SD) | 20 (12.0) |
| Previous antidepressant medication trials, mean (SD) | 4.68 (1.9) |
| QIDS-SRa score at screening, mean (SD) | 17.05 (3.53) |
| Comorbid Psychiatric Conditions, n (%) | |
| Anxiety Disorders | 11 (57.8) |
| Persistent depressive disorder | 7 (36.8) |
| ADHDb | 2 (10.5) |
| CPTSDc | 2 (10.5) |
| Body dysmorphic disorder | 1 (5.2) |
| Prior psychedelic use, n (%) | |
| Any | 8 (42.1) |
| Psilocybin | 7 (36.8) |
| LSDd | 5 (26.3) |
| MDMAe | 2 (10.5) |
| Time since last use of hallucinogens range (years) | 3–24 |
a Quick Inventory of Depressive Symptomatology Self-Report. b Attention-Deficit/Hyperactivity Disorder. c Complex posttraumatic stress disorder. d Lysergic acid diethylamide. e Methylenedioxymethamphetamine.